Edwards' RESILIA valves show 98% durability after a decade in landmark trial

Edwards Lifesciences has released 10-year results from its COMMENCE aortic trial. The study highlights the long-term performance of surgical valves featuring RESILIA tissue. Over half a million patients globally have already received these innovations. The COMMENCE trial tracked patients treated with Edwards' surgical valves. At 10 years, 97.9% remained free from structural valve deterioration (SVD). Freedom from reoperation due to SVD stood at 97.8%.

The valves also demonstrated strong hemodynamic stability over time. Non-structural valve dysfunction was rare, with 98.6% of patients unaffected after a decade. These findings suggest durable performance in managing aortic stenosis.

RESILIA tissue technology is now used across Edwards' surgical and transcatheter products. Clinical evidence increasingly supports earlier intervention in valve disease treatment. This approach aims to reduce the long-term burden on patients and healthcare systems.

In the Asia-Pacific region alone, over 30,000 patients have received Edwards' RESILIA-based valves. Valvular heart disease remains a major challenge in the area, driving demand for reliable, long-lasting solutions. The 10-year data reinforces the durability of Edwards' RESILIA valves in treating aortic stenosis. With over 500,000 patients treated worldwide, the technology continues to expand across surgical and transcatheter platforms. These results may influence future treatment strategies for valve disease management.